ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT)

Jae Duck Choi(Eulji University), Seong Il Seo(Samsung Medical Center)
Scientific Reports
November 9, 2021
10.1038/s41598-021-01003-0
Cited by 22

Related Papers

Inhibition of PREX1 Reverses Enzalutamide Resistance in Castration-Resistant Prostate Cancer
|The World Journal of Men s Health|2025|1
ISL1 Romotes Enzalutamide Resistance in Castration-resistant Prostate Cancer (CRPC) through Epithelial to Mesenchymal Transition (EMT)
|Research Square|2021|0